

# CUMBERLAND PHARMACEUTICALS INC Reported by KAZIMI A J

## FORM 4

(Statement of Changes in Beneficial Ownership)

## Filed 03/18/25 for the Period Ending 03/17/25

Address 2525 WEST END AVENUE SUITE 950 NASHVILLE,, TN, 37203 Telephone 615-255-0068 CIK 0001087294 Symbol CPIX Fiscal Year 12/31

Powered By EDGAR Online

https://www.edgar-online.com

© Copyright 2025, EDGAR Online LLC, a subsidiary of OTC Markets Group. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online LLC, a subsidiary of OTC Markets Group, Terms of Use.



Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer			
	(Check all applicable)			
CUMBERLAND				
PHARMACEUTICALS INC [ CPIX ]	_X_Director _X_10% Owner			
3. Date of Earliest Transaction (MM/DD/YYYY)	X_Officer (give title below) Other (specify below)			
	Chairman and CEO			
3/17/2025				
4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line)			
	X _ Form filed by One Reporting Person Form filed by More than One Reporting Person			
	CUMBERLAND PHARMACEUTICALS INC [ CPIX ] 3. Date of Earliest Transaction (MM/DD/YYYY) 3/17/2025			

#### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

				-	-			-		
1.Title of Security	2. Trans. Date	2A. Deemed	3. Trans. Code		4. Securities Acquired (A)			5. Amount of Securities Beneficially Owned	6.	7. Nature
(Instr. 3)		Execution	(Instr. 8) o		or Disposed of (D)			Following Reported Transaction(s)	Ownership	of Indirect
		Date, if any			(Instr. 3, 4 and 5)			(Instr. 3 and 4)	Form:	Beneficial
									Direct (D)	Ownership
									or Indirect	(Instr. 4)
						(A) or			(I) (Instr.	
			Code	V	Amount	(D)	Price		4)	
Common Stock	3/17/2025		F		3,558 <u>(1)</u>	D	\$5.17	5,698,738	D	

#### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

	Conversion Date or Exercise Price of Derivative		3A. Deemed Execution Date, if any	Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		1		Securities Underlying Derivative Security		Derivative Security (Instr. 5)	Securities Beneficially Owned	Ownership Form of Derivative Security:	Beneficial Ownership (Instr. 4)
	Security			Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Following Reported Transaction(s) (Instr. 4)	Direct (D) or Indirect (I) (Instr. 4)	
Options (right to buy)	\$5.17	3/17/2025		Α		100,000		3/17/2029	3/17/2030	Common Stock	100,000	\$5.17	468,000	D	

#### **Explanation of Responses:**

(1) This transaction represents shares withheld/purchased by the Company to cover the tax withholding obligations for the vesting of shares.

### **Reporting Owners**

Reporting Owner Name / Address	Relationships					
Reporting Owner Warne / Address	Director	10% Owner	Officer	Other		
KAZIMI A J 1600 WEST END AVE. SUITE 1300 NASHVILLE, TN 37203	x	X	Chairman and CEO			

#### Signatures

\*

A.J. Kazimi by /s/ John Hamm as attorney-in-fact	3/18/2025		
**Signature of Reporting Person	Date		

\*\*Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.